Related Experiment Videos
Treatment of overt CNS leukemia
The American Journal of Pediatric Hematology/Oncology
|January 1, 1979
Summary
Treating childhood CNS leukemia with methotrexate and radiotherapy improves remission rates but causes toxicity. Researchers are exploring ways to reduce treatment side effects while maintaining efficacy.
Area of Science:
- Pediatric Oncology
- Hematology
- Neuro-oncology
Background:
- Central nervous system (CNS) leukemia in children presents a significant challenge.
- Overt CNS leukemia requires intensive treatment to achieve prolonged remissions.
Purpose of the Study:
- To review current treatment strategies for overt CNS leukemia in children.
- To discuss methods for mitigating treatment-related toxicities, particularly neurotoxicity.
Main Methods:
- Analysis of existing literature on methotrexate and CNS radiotherapy for pediatric CNS leukemia.
- Evaluation of strategies to reduce toxicity associated with intrathecal methotrexate administration.
Main Results:
- Combined methotrexate and CNS radiotherapy offer the best chance for prolonged remissions.
- Radiotherapy's neurotoxicity is linked to dosage; lower doses may reduce this effect.
- Intrathecal methotrexate toxicity can be reduced by using Elliot's B, combining with hydrocortisone, or using age-based dosing.
Conclusions:
- Prophylactic CNS therapy has decreased the incidence of CNS leukemia.
- CNS relapses, though less frequent, carry a poor prognosis and require ongoing research.
- Optimizing treatment protocols is crucial to balance efficacy and reduce neurotoxicity in pediatric CNS leukemia management.